+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

NTD Treatment Market 2020-2026

  • PDF Icon


  • August 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5148152
Global NTD Treatment Market Size, Share & Trends Analysis Report By disease (Dengue, Rabies, Trachoma, Buruli ulcer, leprosy, Chagas disease, and Others), By Treatment (Drugs and Vaccines), By End-Use (Government & Individual) Forecast Period 2020-2026.

The global NTD treatment market is anticipated to grow at a CAGR 8% during the forecast period. NTDs are recognized as a public health problem by the WHO for the populations living in tropical environments and various difficult-to-access areas especially in developing economies. Most severely impacted populations include the communities inhabiting rural areas, and urban slums. Major factors driving the NTD treatment market include the surge in the funding to the R&D companies by government and non-government organizations for the development and distribution of NTD treatments drugs and vaccines.

The global NTD treatment drug market is segmented based on disease, treatment, and end-user. Based on the disease, the market is sub-segmented into dengue, rabies, trachoma, Buruli ulcer, leprosy, Chagas disease, and others. Further, based on the treatment, the market is bifurcated into drugs and vaccines. By end-user, the market is divided into government and individual. Individual segment is expected to witness significant growth during the forecast period.

The global NTD Treatment market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. The rest of the world is expected to showcase a significant market growth during the forecast period. The growth in the region is owing to the increasing cases of NTD, owing to poor sanitation practices. According to the World Health Organization (WHO) estimation, nearly 40% of the NTD impacted population lives in the African region.

The key players of the global NTD treatment market include AbbVie Inc., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Humanigen Inc., Merck KGaA, Takeda Pharmaceutical Co. Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger, and acquisition, collaborations with government, funding, new drug launches, and various other advancements to stay competitive in the market.

Research Methodology:

The market study of the global NTD treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for the drug manufacturers, hospitals & clinics, drug R&D company, and other related industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global NTD Treatment Market Research and Analysis by Disease
2. Global NTD Treatment Market Research and Analysis by Treatment
3. Global NTD Treatment Market Research and Analysis by End User

The Report Covers:
  • Comprehensive research methodology of the global NTD treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global NTD treatment market.
  • Insights about market determinants which are stimulating the global NTD treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Business Functions and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. AbbVie Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. Eisai Co., Ltd. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. F. Hoffmann-La Roche Ltd. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Humanigen, Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. Merck KGaA Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Global NTD Treatment Market by Disease
5.1.1. Dengue
5.1.2. Rabies
5.1.3. Trachoma
5.1.4. Buruli ulcer
5.1.5. Leprosy
5.1.6. Chagas disease
5.1.7. Others
5.2. Global NTD Treatment Market by Treatment
5.2.1. Drugs
5.2.2. Vaccines
5.3. Global NTD Treatment Market by End-User
5.3.1. Government/ Public
5.3.2. Individual
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. Western Europe
6.2.2. Eastern Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. ASEAN
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
6.4.1. Latin America
6.4.2. Middle East
6.4.3. Africa
7. Company Profiles
7.1. Abbott Laboratories
7.2. AbbVie Inc.
7.3. Astellas Pharma Inc.
7.4. Bayer AG
7.5. CadilaHealthcare Ltd.
7.6. Daiichi Sankyo Company, Ltd.
7.7. Eisai Co., Ltd.
7.8. Eli Lilly & Co.
7.9. F. Hoffmann-La Roche Ltd.
7.10. Gilead Sciences, Inc.
7.11. GlaxoSmithKline plc
7.12. Humanigen, Inc.
7.13. Insud Pharma S.L.U.
7.14. Merck KGaA
7.15. Novartis AG
7.16. Oblita Therapeutics
7.17. Pfizer Inc.
7.18. Sanofi SA
7.19. Sun Pharmaceutical Industries Ltd.
7.20. Takeda Pharmaceutical Company Ltd.
7.21. Teva Pharmaceutical Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • CadilaHealthcare Ltd.
  • Daiichi Sankyo Company, Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Humanigen, Inc.
  • Insud Pharma S.L.U.
  • Merck KGaA
  • Novartis AG
  • Oblita Therapeutics
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceutical Industries Ltd.